Trials / Completed
CompletedNCT01429441
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- ThromboGenics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
Detailed description
The present study is designed to assess anatomical and functional outcomes following a single intravitreal injection of ocriplasmin 0.125mg in subjects with symptomatic vitreomacular adhesion (VMA)/ (VMT) including macular hole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ocriplasmin | 0.125 mg single intravitreal injection |
| OTHER | Sham injection | Sham injection |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2011-09-07
- Last updated
- 2016-03-14
- Results posted
- 2016-01-11
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01429441. Inclusion in this directory is not an endorsement.